TYRA
Tyra Biosciences, Inc.
Biotechnology
Market Cap$1.77B
5Y Perf.+87.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TYRA vs NUVL
Revenue, margins, valuation, and 5-year total return — side by side.
NUVL
Nuvalent, Inc.
Biotechnology
Market Cap$7.53B
5Y Perf.+354.1%
TYRA vs NUVL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TYRA | NUVL |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.77B | $7.53B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-120M | $-450M |
| Total Debt | $6M | $0.00 |
| Cash & Equiv. | $77M | $262M |
TYRA vs NUVL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TYRA
NUVL
| Stock | Sep 21 | May 26 | Return |
|---|---|---|---|
| Tyra Biosciences, I… (TYRA) | 100 | 187.0 | +87.0% |
| Nuvalent, Inc. (NUVL) | 100 | 454.1 | +354.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TYRA vs NUVL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TYRA and NUVL are tied at the top with 2 categories each — the right choice depends on your priorities. Nuvalent, Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
TYRA
Tyra Biosciences, Inc.
The Income Pick
TYRA has the current edge in this matchup, primarily because of its strength in income & stability and growth exposure.
- beta 0.75
- EPS growth -33.1%
- Lower volatility, beta 0.75, Low D/E 2.2%, current ratio 14.67x
Best for: income & stability and growth exposure
NUVL
Nuvalent, Inc.
The Long-Run Compounder
NUVL is the clearest fit if your priority is long-term compounding.
- 446.1% 10Y total return vs TYRA's 26.5%
- 1.1% revenue growth vs TYRA's -38.9%
- -37.8% ROA vs TYRA's -38.4%, ROIC -32.5% vs -44.8%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NUVL | 1.1% revenue growth vs TYRA's -38.9% |
| Stability / Safety | TYRA | Beta 0.75 vs NUVL's 1.09 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | TYRA | +260.4% vs NUVL's +53.5% |
| Efficiency (ROA) | NUVL | -37.8% ROA vs TYRA's -38.4%, ROIC -32.5% vs -44.8% |
TYRA vs NUVL — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNUVLLAGGINGTYRA
TYRATyra Biosciences, Inc.
0leads
NUVLNuvalent, Inc.
4leads
6 Total Categories
CATEGORYLEADERvs TYRAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NUVL1/1
Valuation MetricsMultiples, price ratios, and targets
NUVL2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NUVL5/6
Total Returns1Y, 3Y, 5Y total returns with dividends
NUVL4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NUVL leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
TYRA and NUVL operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | TYRATyra Biosciences,… | NUVLNuvalent, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$132M | -$346M |
| Net IncomeAfter-tax profit | -$120M | -$450M |
| Free Cash FlowCash after capex | -$95M | -$313M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -32.6% | -17.8% |
NUVL leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
NUVL leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | TYRATyra Biosciences,… | NUVLNuvalent, Inc. |
|---|---|---|
| Market CapShares × price | $1.8B | $7.5B |
| Enterprise ValueMkt cap + debt − cash | $1.7B | $7.3B |
| Trailing P/EPrice ÷ TTM EPS | -16.37x | -17.50x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 7.57x | 5.96x |
| Price / FCFMarket cap ÷ FCF | — | — |
NUVL leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
NUVL leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
TYRA delivers a -41.2% return on equity — every $100 of shareholder capital generates $-41 in annual profit, vs $-43 for NUVL.
| Metric | TYRATyra Biosciences,… | NUVLNuvalent, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -41.2% | -42.8% |
| ROA (TTM)Return on assets | -38.4% | -37.8% |
| ROICReturn on invested capital | -44.8% | -32.5% |
| ROCEReturn on capital employed | -43.3% | -34.4% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 1 |
| Debt / EquityFinancial leverage | 0.02x | — |
| Net DebtTotal debt minus cash | -$72M | -$262M |
| Cash & Equiv.Liquid assets | $77M | $262M |
| Total DebtShort + long-term debt | $6M | $0 |
| Interest CoverageEBIT ÷ Interest expense | — | -26.85x |
NUVL leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
NUVL leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NUVL five years ago would be worth $54,613 today (with dividends reinvested), compared to $12,654 for TYRA. Over the past 12 months, TYRA leads with a +260.4% total return vs NUVL's +53.5%. The 3-year compound annual growth rate (CAGR) favors NUVL at 39.5% vs TYRA's 34.6% — a key indicator of consistent wealth creation.
| Metric | TYRATyra Biosciences,… | NUVLNuvalent, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +22.8% | +1.5% |
| 1-Year ReturnPast 12 months | +260.4% | +53.5% |
| 3-Year ReturnCumulative with dividends | +143.7% | +171.2% |
| 5-Year ReturnCumulative with dividends | +26.5% | +446.1% |
| 10-Year ReturnCumulative with dividends | +26.5% | +446.1% |
| CAGR (3Y)Annualised 3-year return | +34.6% | +39.5% |
NUVL leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TYRA and NUVL each lead in 1 of 2 comparable metrics.
Risk & Volatility
TYRA is the less volatile stock with a 0.75 beta — it tends to amplify market swings less than NUVL's 1.09 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NUVL currently trades 90.6% from its 52-week high vs TYRA's 80.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TYRATyra Biosciences,… | NUVLNuvalent, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.75x | 1.09x |
| 52-Week HighHighest price in past year | $40.65 | $113.02 |
| 52-Week LowLowest price in past year | $8.75 | $63.56 |
| % of 52W HighCurrent price vs 52-week peak | +80.9% | +90.6% |
| RSI (14)Momentum oscillator 0–100 | 43.1 | 52.9 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 544K |
Evenly matched — TYRA and NUVL each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TYRA as "Buy" and NUVL as "Buy". Consensus price targets imply 53.5% upside for TYRA (target: $51) vs 41.0% for NUVL (target: $144).
| Metric | TYRATyra Biosciences,… | NUVLNuvalent, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $50.50 | $144.40 |
| # AnalystsCovering analysts | 7 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NUVL leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallNuvalent, Inc. (NUVL)Leads 4 of 6 categories
Loading custom metrics...
TYRA vs NUVL: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TYRA or NUVL a better buy right now?
Analysts rate Tyra Biosciences, Inc.
(TYRA) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TYRA or NUVL?
Over the past 5 years, Nuvalent, Inc.
(NUVL) delivered a total return of +446. 1%, compared to +26. 5% for Tyra Biosciences, Inc. (TYRA). Over 10 years, the gap is even starker: NUVL returned +446. 1% versus TYRA's +26. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TYRA or NUVL?
By beta (market sensitivity over 5 years), Tyra Biosciences, Inc.
(TYRA) is the lower-risk stock at 0. 75β versus Nuvalent, Inc. 's 1. 09β — meaning NUVL is approximately 45% more volatile than TYRA relative to the S&P 500.
04Which is growing faster — TYRA or NUVL?
On earnings-per-share growth, the picture is similar: Tyra Biosciences, Inc.
grew EPS -33. 1% year-over-year, compared to -48. 9% for Nuvalent, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TYRA or NUVL?
Tyra Biosciences, Inc.
(TYRA) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Nuvalent, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TYRA leads at 0. 0% versus 0. 0% for NUVL. At the gross margin level — before operating expenses — TYRA leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TYRA or NUVL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TYRA or NUVL better for a retirement portfolio?
For long-horizon retirement investors, Tyra Biosciences, Inc.
(TYRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 75)). Both have compounded well over 10 years (TYRA: +26. 5%, NUVL: +446. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TYRA and NUVL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.